Published:
Riverside Partners Portfolio Company J-Pac Names New CEO
BOSTON, July 15 /PRNewswire/ -- Riverside Partners, aBoston based private
equity firm focusing on healthcare and technology businesses, is pleased to
announce that The J-Pac and Doyen Medipharm Group ("JPDM" or the "Company"), a
leader in contract manufacturing and packaging machinery for the medical
device and pharmaceutical industries, has named Dr. P. Richard Eagling as the
Company's new Chief Executive Officer and a board member. Richard succeeds
Bill McLaughlin, who led JPDM successfully for the past 8 years. Mr.
McLaughlin will remain active with the Group as its Vice Chairman and a member
of the board of directors.
Dr. Eagling brings to J-Pac and Doyen Medipharm 30 years of industry
experience in the medical device, diagnostic, life science and
biopharmaceutical fields. Dr. Eagling has been responsible for leading large
divisions of several companies including Ciba Corning Diagnostics, Oridion
Medical, Integrated Biosystems and most recently Stedim Biosystems.
Additionally, Dr. Eagling previously served as the President and CEO of Gamera
Bioscience.
"We believe Richard's experience and proven success with global companies,
working in organizations both larger and smaller than J-Pac, will help us
continue to capitalize on the tremendous opportunities for growth ahead of us.
We are sure that his commitment, integrity, and interpersonal style will fit
extremely well with the culture and values of our entire team," said Brian
Guthrie, a General Partner at Riverside Partners and Chairman of the Board of
J-Pac.
"I am extremely excited to build upon the great medical manufacturing
platform that Bill McLaughlin and his team has created at J-Pac and Doyen
Medipharm and am looking forward to leading the Company's next phase of
growth. We will continue to focus on providing high quality advanced drug
delivery and related medical products to the world's leading OEMs," said Dr.
Eagling.
About J-Pac and Doyen Manufacturing
Headquartered inSomersworth, NH, J-Pac is a leading contract manufacturer
and equipment maker for medical device and biopharmaceutical OEMs. J-Pac's
contract manufacturing division specializes in medical devices, medical
packaging and trays, and advanced medical device and drug delivery systems.
Through its Doyen Division, J-Pac also provides precision high-volume
production equipment to medical device and biopharmaceutical OEMs around the
world.
About Riverside Partners
Founded in 1989, Riverside Partners is a middle market private equity firm
currently investing Riverside Fund III, L.P. The fund focuses on
growth-oriented companies in the healthcare and technology industries.
Riverside is particularly experienced at partnering with founders, owners and
management teams and it brings substantial domain expertise and operating
experience to its portfolio companies. The partners atRiverside have managed
more than $500 million in investments in over 50 companies. We are currently
focused on companies with revenues between $20 - $200 million and with $5 -
$25 million of EBITDA.
SOURCE Riverside Partners
Copyright © 2008, PRNewswire
Copyright © 2008, NewsBlaze,
Daily NewsTags: Healthcare, Computers and Electronics, Pharmaceuticals, Health, High Tech, massachusetts, new hampshire
_ _Is your favorite bookmark site missing?
Ask for it.
Search News
Daily News
